Characterization of novel checkpoint kinase 1 inhibitors by in vitro assays and in human cancer cells treated with topoisomerase inhibitors

Life Sciences

Volumn 89, Issue 7-8, 2011, Pages 259-268

  Ferry, Gilles ^a   Studeny, Aurélie ^a   Bossard, Céline ^a   Kubara, Philip M ^d   Zeyer, Denis ^b   Renaud, Jean Paul ^b   Casara, Patrick ^a   De Nanteuil, Guillaume ^a   Wierzbicki, Michel ^a   Pfeiffer, Bruno ^a   Prudhomme, Michelle ^c   Leonce, Stephane ^a   Pierré, Alain ^a   Boutin, Jean A ^a   Golsteyn, Roy M ^d  

^a INSTITUT DE RECHERCHES SERVIER   (France)

^b NovAliX   (France)

^c UNIVERSITÉ CLERMONT AUVERGNE   (France)

^d UNIVERSITY OF LETHBRIDGE   (Canada)

Author keywords

Camptothecin; Cell cycle; Checkpoint adaptation; Checkpoint kinase 1; DNA damage; Mitosis

Indexed keywords

CARBAZOLE DERIVATIVE; CHECKPOINT KINASE 1; CHECKPOINT KINASE 1 INHIBITOR; DEBROMOHYMENIALDISINE; HYMENIALDISINE; INDOLE DERIVATIVE; PROTEIN SERINE THREONINE KINASE INHIBITOR; S 27888; S 29285; S 29859; S 39614; S 41842; S 74259; SUNITINIB; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BIOASSAY; CELL ASSAY; CELL STRAIN HCT116; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG IDENTIFICATION; ENZYME ACTIVITY; ENZYME ASSAY; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL; MITOSIS; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION;

ADENOCARCINOMA; ANIMALS; CARBAZOLES; CELL LINE, TUMOR; CELL SURVIVAL; COLONIC NEOPLASMS; DNA DAMAGE; DNA, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; PROTEIN KINASES; SPODOPTERA; TOPOISOMERASE I INHIBITORS;

EID: 79960980163     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2011.06.010     Document Type: Article

References (60)

1. Anizon F, Golsteyn RM, Leonce S, Pfeiffer B, Prudhomme M. A three-step synthesis from rebeccamycin of an efficient checkpoint kinase 1 inhibitor. Eur J Med Chem 2009;44:2234-8.
2. Bartek J, Lukas J. Pathways governing the G1/S transition and their response to DNA damage. FEBS Lett 2001;490:117-22. (Pubitemid 32171930)
3. Blasina A, Hallin J, Chen E, Arango ME, Kraynov E, Register J, et al. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Mol Cancer Ther 2008;7:2394-404.
4. Borgne A, Versteege I, Mahe M, Studeny A, Leonce S, Naime I, et al. Analysis of cyclin B1 and CDK activity during apoptosis induced by camptothecin treatment. Oncogene 2006;25:7361-72. (Pubitemid 44853427)
5. Bunch RT, Eastman A. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin Cancer Res 1996;2:791-7. (Pubitemid 26168931)
6. Busby EC, Leistritz DF, Abraham RT, Karnitz LM, Sarkaria JN. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res 2000;60:2108-12. (Pubitemid 30225168)
7. Cahuzac N, Studény A, Marshall K, Versteege I, Wetenhall K, Pfeiffer B, et al. An unusual DNA binding compound, S23906, induces mitotic catastrophe in cultured human cells. Cancer Lett 2010;289:178-87.
8. Capasso H, Palermo C, Wan S, Rao H, John UP, O'Connell MJ, et al. Phosphorylation activates Chk1 and is required for checkpoint-mediated cell cycle arrest. J Cell Sci 2002;115:4555-64. (Pubitemid 36004415)
9. Carrasco C, Vezin H, Wilson WD, Ren J, Chaires JB, Bailly C. DNA binding properties of the indolocarbazole antitumor drug NB-506. Anticancer Drug Des 2001;16:99-107. (Pubitemid 34269745)
10. Chen P, Luo C, Deng Y, Ryan K, Registar J, Margosiak S, et al. The 1.7 A crystal structure of human cell cycle checkpoint kinase Chk1: implications for Chk1 regulation. Cell 2000;100:681-92.
11. Chen Z, Xiao Z, Chen J, Ng SC, Sowin T, Sham H, et al. Human Chk1 expression is dispensable for somatic cell death and critical for sustaining G2 DNA damage checkpoint. Mol Cancer Ther 2003;2:543-8.
12. Cliby WA, Lewis KA, Lilly KK, Kaufmann SH. S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function. J Biol Chem 2002;277:1599-606. (Pubitemid 34968919)
13. Curman D, Cinel B, Williams DE, Rundle N, Block WD, Goodarzi AA, et al. Inhibition of the G2 DNA damage checkpoint and of protein kinases Chk1 and Chk2 by the marine sponge alkaloid debromohymenialdisine. J Biol Chem 2001;276:17914-9.
14. Eastman A, Kohn EA, Brown MK, Rathman J, Livingstone M, Blank DH, et al. A novel indolocarbazole, ICP-1, abrogates DNA damage-induced cell cycle arrest and enhances cytoxicity: similarities and differences to the cell cycle checkpoint abrogator UCN-01. Mol Cancer Ther 2002;1:1067-78.
15. Flatten K, Dai NT, Vroman BT, Loegering D, Erlichman C, Karnitz LM, et al. The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons. J Biol Chem 2005;280:14349-55. (Pubitemid 40517339)
16. Hartwell LH, Weinert TA. Checkpoints: controls that ensure the order of cell cycle events. Science 1989;246:629-34. (Pubitemid 19283354)
17. Hendzel MJ, Wei Y, Mancini MA, Van Hooser A, Ranalli T, Brinkley BR, et al. Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma 1997;106:348-60. (Pubitemid 27510848)
18. Henon H, Anizon F, Golsteyn RM, Leonce S, Hofmann R, Pfeiffer B, et al. Synthesis and biological evaluation of new dipyrrolo[3,4-a:3,4-c]carbazole-1,3, 4,6-tetraones, substituted with various saturated and unsaturated side chains via palladium catalyzed cross-coupling reactions. Bioorg Med Chem 2006;14:3825-34.
19. Henon H, Messaoudi S, Anizon F, Aboab B, Kucharczyk N, Leonce S, et al. Bis-imide granulatimide analogues as potent Checkpoint 1 kinase inhibitors. Eur J Pharmacol 2007;554:106-12. (Pubitemid 44879419)
20. Henon H, Conchon E, Hugon B, Messaoudi S, Golsteyn RM, Prudhomme M. Pyrrolocarbazoles as checkpoint 1 kinase inhibitors. Anticancer AgentsMed Chem 2008;8:577-97.
21. Hugon B, Anizon F, Bailly C, Golsteyn RM, Pierre A, Leonce S, et al. Synthesis and biological activities of isogranulatimide analogues. Bioorg Med Chem 2007;15:5965-80. (Pubitemid 47043465)
22. Jiang X, Zhao B, Britton R, Lim LY, Leong D, Sanghera JS, et al. Inhibition of Chk1 by the G2 DNA damage checkpoint inhibitor isogranulatimide. Mole Cancer Ther 2004;3:1221-7. (Pubitemid 39440167)
23. Karsenti E, Bravo R, Kirschner M. Phosphorylation changes associated with the early cell cycle in Xenopus eggs. Dev Biol 1987;119:442-53. (Pubitemid 17026451)
24. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004;432:316-23. (Pubitemid 39551659)
25. Kohn EA, Yoo GH, Eastman A. The protein kinase C inhibitor Gö6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle components. Cancer Res 2003;63:31-5. (Pubitemid 36070415)
26. Kuntz K, O'Connell MJ. The G(2) DNA damage checkpoint: could this ancient regulator be the Achilles heel of cancer? Cancer Biol Ther 2009;8:1433-9.
27. Langer T, Hoffmann R, Bryant S, Lesur B. Hit finding: towards 'smarter' approaches. Curr Opin Pharmacol 2009;9:589-93.
28. Leonce S, Kraus-Berthier L, Golsteyn RM. Generation of replication-dependent double-strand breaks by the novel N2-G-alkylator S23906-1. Cancer Res 2006;66:7203-10. (Pubitemid 44197699)
29. Levis M, Small D. Novel FLT3 tyrosine kinase inhibitors. Expert Opin Investig Drugs 2003;12:1951-62. (Pubitemid 38008543)
30. Liu Q, Guntuku S, Cui X, Matsuoka S, Cortez D, Tamai K, et al. Chk1 is an essential kinase that is regulated by Atr and required for the G2/M DNA damage checkpoint. Genes Dev 2000;14:1448-59. (Pubitemid 30421838)
31. Mailand N, Falck J, Lukas C, Syljuasen RG, Welcker M, Bartek J, et al. Rapid destruction of human Cdc25A in response to DNA damage. Science 2000;288:1425-9. (Pubitemid 30366329)
32. Marminon C, Anizon F, Moreau P, Pfeiffer B, Pierre A, Golsteyn RM, et al. Rebeccamycin derivatives as dual DNA-damaging agents and potent checkpoint kinase 1 inhibitors. Mol Pharmacol 2008;74:1620-9.
33. Meijer L, Thunnissen A-MWH, White AW, Garnier M, Nikolic M, Tsai LH, et al. Inhibition of cyclin-dependent kinases, GSK-3B and CK1 by hymenialdisine, a marine sponge constituent. Chem Biol 2000;7:51-63. (Pubitemid 30141925)
34. Melo J, Toczyski D. A unified view of the DNA-damage checkpoint. Curr Opin Cell Biol 2002;14:237-45. (Pubitemid 34219514)
35. Monks A, Harris ED, Vaigro-Wolff A, Hose CD, Connelly JW, Sausville EA. UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines. Invest New Drugs 2000;18:95-107. (Pubitemid 30261284)
36. Moreau P, Sancelme M, Bailly C, Leonce S, Pierre A, Hickman J, et al. Synthesis and biological activities of indolocarbazoles bearing amino acid residues. Eur J Med Chem 2001;36:887-97. (Pubitemid 34033700)
37. Morgan MA, Parsels LA, Parsels JD, Mesiwala AK, Maybaum J, Lawrence TS. Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine. Cancer Res 2005;65:6835-42. (Pubitemid 41060722)
38. Morgan MA, Parsels LA, Parsels JD, Lawrence TS, Maybaum J. The relationship of premature mitosis to cytotoxicity in response to checkpoint abrogation and antimetabolite treatment. Cell Cycle 2006;5:1983-8. (Pubitemid 44435305)
39. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24. (Pubitemid 46089672)
40. Parmentier JG, Portevin B, Golsteyn RM, Pierre A, Hickman J, Gloanec P, et al. Synthesis and CHK1 inhibitory potency of hymenialdisine analogues. Bioorg Med Chem Lett 2008;7:7.
41. Paull TT, Rogakou EP, Yamazaki V, Kirchgessner CU, Gellert M, Bonner WM. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol 2000;10:886-95. (Pubitemid 30647617)
42. Peng CY, Graves PR, Thoma RS, Wu Z, Shaw AS, Piwnica-Worms H. Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 1997;277:1501-5. (Pubitemid 27449237)
43. Porter LA, Singh G, Lee JM. Abundance of cyclin B1 regulates γ-radiation-induced apoptosis. Blood 2000;95:2645-50. (Pubitemid 30210545)
44. Portevin B, Golsteyn RM, Pierré A, Hickman JA, De Nanteuil G. An expeditive multigram preparation of the marine protein kinase inhibitor debromohymenialdisine. Tetrahedron Lett 2004;44:9263-5. (Pubitemid 37485814)
45. Rivory LP, Haaz MC, Canal P, Lokiec F, Armand JP, Robert J. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials. Clin Cancer Res 1997;3:1261-6. (Pubitemid 27362386)
46. Roberge M, Berlinck RGS, Xu L, Anderson HJ, Lim LY, Curman D, et al. High-through put assay for G2 checkpoint inhibitors and identification of the structurally novel compound isogranulatimide. Cancer Res 1998;58:5701-6. (Pubitemid 29006409)
47. Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, Piwnica-worms H, et al. Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through CDC25. Science 1997;277:1497-501. (Pubitemid 27449236)
48. Sanz M, Burnett A, Lo-Coco F, Lowenberg B. FLT3 inhibition as a targeted therapy for acute myeloid leukemia. Curr Opin Oncol 2009;21:594-600.
49. Shao RG, Cao CX, Shimizu T, O'Connor PM, Kohn KW, Pommier Y. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res 1997;57:4029-35. (Pubitemid 27427693)
50. Sorensen C, Sylijuasen RG, Falck J, Schroeder T, Rönnstrand L, Khanna KK, et al. Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. Cancer Cell 2003;3:247-58. (Pubitemid 37443880)
51. Tanizawa A, Fujimori A, Fujimori Y, Pommier Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 1994;86:836-42. (Pubitemid 24164661)
52. Tao Y, Leteur C, Yang C, Zhang P, Castedo M, Pierre A, et al. Radiosensitization by Chir-124, a selective CHK1 inhibitor: effects of p53 and cell cycle checkpoints. Cell Cycle 2009;8:1196-205.
53. Tse AN, Rendahl KG, Sheikh T, Cheema H, Aardalen K, Embry M, et al. CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo. Clin Cancer Res 2007;13:591-602. (Pubitemid 46225366)
54. Vanderpool D, Johnson TO, Ping C, Bergqvist S, Alton G, Phonephaly S, et al. Characterization of the CHK1 allosteric inhibitor binding site. Biochemistry 2009;48:9823-30.
55. Xiao Z, Chen Z, Gunasekera AH, Sowin TJ, Rosenberg SH, Fesik S, et al. Chk1mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents. J Biol Chem 2003;278:21767-73. (Pubitemid 36792580)
56. Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL, et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther 2008;7:2955-66.
57. Zhao H, Piwnica-Worms H. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol Cell Biol 2001;21:4129-39. (Pubitemid 32565295)
58. Zhao B, Bower MJ, McDevitt PJ, Zhao H, Davis ST, Johanson KO, et al. Structural basis for Chk1 inhibition by UCN-01. J Biol Chem 2002a;277:46609-15. (Pubitemid 35417660)
59. Zhao H, Watkins JL, Piwnica-worms H. Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc Natl Acad Sci 2002b;99:14795-800. (Pubitemid 35334563)
60. Zhou BB, Anderson HJ, Roberge M. Targeting DNA checkpoint kinases in cancer therapy. Cancer Biol Ther 2003;2:S16-22.